Evidence map›Paper›PMID 41600861›Full record

ReviewViruses2026

Broth Optical Density-Based Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and Time-Kill.

Stephen T Abedon

Abstract readReview
In one paragraph

Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Stephen T AbedonDepartment of Microbiology, The Ohio State University, Mansfield, OH 44906, USA.ORCID 0000-0001-9151-2375

Funding

The impact of bacteriophage therapy on wound infection dynamicsR01AI169865 · NIAID · OHIO STATE UNIVERSITY · PI Daniel J Wozniak · 2022 to 2026
$3.7M
NIAID NIH HHS R01 AI169865United States Public Health Service R01AI169865
6 · The paper itself

Abstract

Phage therapy is the use of bacterial viruses, or bacteriophages, as antibacterial agents. It has been in use for over 100 years and is becoming increasingly common clinically. The first steps of phage therapy include identification of bacteria to be targeted and then obtaining phages with appropriate host ranges. This is followed by various approaches to in vitro phage characterization. Increasingly common for phage phenotypic characterization is the use of kinetic microtiter plate readers. They can both decrease workloads and increase throughput, especially relative to analyses that require plating on agar-based media. These colorimetric/turbidimetric/optical density approaches primarily assess phage-induced culture-wide bacterial lysis, in the shorter term, or instead the phage potential to suppress phage-resistance evolution over longer time frames. Considered here are methods relevant to phage characterization especially for phage-therapy purposes. Discussed are turbidity-reduction assays, determinations of phage antibacterial virulence, and related time-kill curve analysis. All are or can be optical density-based approaches to assessing phage-based bacterial reduction. Emphasis is placed on consideration of the utilities, limitations, and intersections of these similar methods. Emphasized is that the start of "Deviation"-where phage-treated culture turbidity diverges from phage-free controls-may represent a superior endpoint for such optical density-based bacterial-reduction protocols.

Indexed as

BacteriaBacterial InfectionsBacteriophagesPhage TherapyAnti-Bacterial AgentsHumansMicrobial ViabilityNephelometry and TurbidimetryVirulenceAnti-Bacterial Agents96-well platebacterial growth reductionbacteriophagebacteriophage therapykinetic assaylysis profileoptical densitytime killtime-killtime-killing

Identifiers

PMID41600861
PMCPMC12846699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.